BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, El-Gamal Y, Harville TO, Hossny E, Mazer B, Nelson R, Secord E, Jordan SC, Stiehm ER, Vo AA, Ballow M. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol 2017;139:S1-S46. [PMID: 28041678 DOI: 10.1016/j.jaci.2016.09.023] [Cited by in Crossref: 247] [Cited by in F6Publishing: 199] [Article Influence: 41.2] [Reference Citation Analysis]
Number Citing Articles
1 Pecoraro A, Crescenzi L, Granata F, Genovese A, Spadaro G. Immunoglobulin replacement therapy in primary and secondary antibody deficiency: The correct clinical approach. International Immunopharmacology 2017;52:136-42. [DOI: 10.1016/j.intimp.2017.09.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
2 Bonam SR, Kaveri SV, Sakuntabhai A, Gilardin L, Bayry J. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients. Cell Rep Med. 2020;1:100016. [PMID: 32562483 DOI: 10.1016/j.xcrm.2020.100016] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 27.0] [Reference Citation Analysis]
3 Piza CFST, Aranda CS, Solé D, Jolles S, Condino-Neto A. Serum Protein Electrophoresis May Be Used as a Screening Tool for Antibody Deficiency in Children and Adolescents. Front Immunol 2021;12:712637. [PMID: 34497609 DOI: 10.3389/fimmu.2021.712637] [Reference Citation Analysis]
4 Güngör A, Yarali N. The use of intravenous immunoglobulin therapy in a tertiary pediatric hospital. Saudi Med J 2020;41:163-7. [PMID: 32020150 DOI: 10.15537/smj.2020.2.24877] [Reference Citation Analysis]
5 Lee JL, Mohamed Shah N, Makmor-Bakry M, Islahudin F, Alias H, Mohd Saffian S. A systematic review of population pharmacokinetic analyses of polyclonal immunoglobulin G therapy. Int Immunopharmacol 2021;97:107721. [PMID: 33962225 DOI: 10.1016/j.intimp.2021.107721] [Reference Citation Analysis]
6 Valle DAD, Santos MLSF, Spinosa MJ, Telles BA, Prando C, Cordeiro ML. GABAA receptor encephalitis associated with human parvovirus B19 virus infection: Case report. Medicine (Baltimore) 2021;100:e26324. [PMID: 34115048 DOI: 10.1097/MD.0000000000026324] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Heimall J, Buckley RH, Puck J, Fleisher TA, Gennery AR, Haddad E, Neven B, Slatter M, Roderick S, Baker KS, Dietz AC, Duncan C, Griffith LM, Notarangelo L, Pulsipher MA, Cowan MJ. Recommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogenic Hematopoietic Cell Transplantation: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant 2017;23:1229-40. [PMID: 28479164 DOI: 10.1016/j.bbmt.2017.04.026] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
8 Varricchi G, Poto R, Ianiro G, Punziano A, Marone G, Gasbarrini A, Spadaro G. Gut Microbiome and Common Variable Immunodeficiency: Few Certainties and Many Outstanding Questions. Front Immunol 2021;12:712915. [PMID: 34408753 DOI: 10.3389/fimmu.2021.712915] [Reference Citation Analysis]
9 Locke KW, Maneval DC, LaBarre MJ. ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Deliv 2019;26:98-106. [PMID: 30744432 DOI: 10.1080/10717544.2018.1551442] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 12.3] [Reference Citation Analysis]
10 Jolles S, Smith BD, Vinh DC, Mallick R, Espinoza G, DeKoven M, Divino V. Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies. Leuk Lymphoma 2021;:1-10. [PMID: 34702119 DOI: 10.1080/10428194.2021.1992761] [Reference Citation Analysis]
11 Overton PM, Shalet N, Somers F, Allen JA. Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review. Patient Prefer Adherence 2021;15:811-34. [PMID: 33907384 DOI: 10.2147/PPA.S303279] [Reference Citation Analysis]
12 Ravindranath MH, Hilali FE, Filippone EJ. Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg. Vaccines (Basel) 2021;9:680. [PMID: 34205517 DOI: 10.3390/vaccines9060680] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Dilley M, Wangberg H, Noone J, Geng B. Primary immunodeficiency diseases treated with immunoglobulin and associated comorbidities. Allergy Asthma Proc 2021;42:78-86. [PMID: 33404391 DOI: 10.2500/aap.2021.42.200113] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Wasserman RL, Garcia D, Greener BN, Kestenberg K, Pinkert A, Mond J, Grossman A. Manufacturing process optimization of ADMA Biologics' intravenous immunoglobulin products, BIVIGAM ® and ASCENIV™. Immunotherapy 2019;11:1423-33. [DOI: 10.2217/imt-2019-0157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Brand A, De Angelis V, Vuk T, Garraud O, Lozano M, Politis D. Review of indications for immunoglobulin (IG) use: Narrowing the gap between supply and demand. Transfusion Clinique et Biologique 2021;28:96-122. [DOI: 10.1016/j.tracli.2020.12.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
16 Chen KH, Wang SF, Wang SY, Yang YP, Wang ML, Chiou SH, Chang YL. Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019. J Chin Med Assoc 2020;83:817-21. [PMID: 32568969 DOI: 10.1097/JCMA.0000000000000375] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
17 Bayry J, Kaveri SV. Kill 'Em All: Efgartigimod Immunotherapy for Autoimmune Diseases. Trends Pharmacol Sci 2018;39:919-22. [PMID: 30201270 DOI: 10.1016/j.tips.2018.08.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
18 Yazdanbakhsh K, Zhong H. IVIg and hemolytic anemia risk: dump the anti-A/B already! Transfusion 2020;60:1337-9. [PMID: 32681818 DOI: 10.1111/trf.15939] [Reference Citation Analysis]
19 Charlet R, Sendid B, Kaveri SV, Poulain D, Bayry J, Jawhara S. Intravenous Immunoglobulin Therapy Eliminates Candida albicans and Maintains Intestinal Homeostasis in a Murine Model of Dextran Sulfate Sodium-Induced Colitis. Int J Mol Sci 2019;20:E1473. [PMID: 30909599 DOI: 10.3390/ijms20061473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
20 Pegler JRM, Castro APBM, Pastorino AC, Dorna MB. Transfusion-related acute lung injury associated to intravenous immunoglobulin infusion in a pediatric patient. Einstein (Sao Paulo) 2020;18:eRC5606. [PMID: 33295434 DOI: 10.31744/einstein_journal/2020RC5606] [Reference Citation Analysis]
21 Pollock RF, Meckley LM. An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland. Clinicoecon Outcomes Res 2018;10:223-9. [PMID: 29692618 DOI: 10.2147/CEOR.S155641] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood 2020;136:925-35. [PMID: 32582924 DOI: 10.1182/blood.2019004000] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 28.0] [Reference Citation Analysis]
23 Wallenhorst C, Patel A, Shebl A, Hubsch A, Simon TL, Martinez C. Anti-A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort study. Transfusion 2020;60:1381-90. [PMID: 32488887 DOI: 10.1111/trf.15859] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Galeotti C, Kaveri SV, Bayry J. Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19). Clin Transl Immunology 2020;9:e1198. [PMID: 33088506 DOI: 10.1002/cti2.1198] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
25 Bittner B, Richter W, Schmidt J. Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities. BioDrugs 2018;32:425-40. [PMID: 30043229 DOI: 10.1007/s40259-018-0295-0] [Cited by in Crossref: 88] [Cited by in F6Publishing: 73] [Article Influence: 29.3] [Reference Citation Analysis]
26 Almaghlouth I, Johnson SR, Pullenayegum E, Gladman D, Urowitz M. Immunoglobulin levels in systemic lupus erythematosus: A narrative review. Lupus 2021;30:867-75. [PMID: 33779380 DOI: 10.1177/09612033211004714] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Mangiola M, Marrari M, Ensor C, Spycher MO, Berger M, Zeevi A. Therapeutic Human IgG Preparations Contain Mixture of HLA Antibodies to Native HLA Antigens and Cryptic Epitopes With Little Clinical Significance. Transplantation 2018;102:2126-32. [PMID: 29877923 DOI: 10.1097/TP.0000000000002312] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Lamb YN, Syed YY, Dhillon S. Immune Globulin Subcutaneous (Human) 20% (Hizentra®): A Review in Chronic Inflammatory Demyelinating Polyneuropathy. CNS Drugs 2019;33:831-8. [DOI: 10.1007/s40263-019-00655-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Monleón Bonet C, Waser N, Cheng K, Tzivelekis S, Edgar JDM, Sánchez-Ramón S. A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants. Expert Rev Clin Immunol 2020;16:911-21. [PMID: 32783541 DOI: 10.1080/1744666X.2020.1807328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Harville T. Can we effectively use radiographic imaging and clinical parameters for making an earlier diagnosis of granulomatous interstitial lung disease in patients with common variable immunodeficiency? Ann Allergy Asthma Immunol 2017;118:529-30. [PMID: 28477784 DOI: 10.1016/j.anai.2017.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
31 Silver JN, Ashbaugh CD, Miles JJ, Wu H, Marecki GT, Hwang JK, Jiao JA, Abrams M, Sullivan EJ, Wesemann DR. Deployment of Transchromosomal Bovine for Personalized Antimicrobial Therapy. Clin Infect Dis 2018;66:1116-9. [PMID: 29272362 DOI: 10.1093/cid/cix977] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
32 Milota T, Bloomfield M, Kralickova P, Jilek D, Novak V, Litzman J, Posova H, Mrazova L, Poloniova J, Prucha M, Rozsival P, Rauschova V, Philipp G, Sediva A. Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin. Clin Ther 2019;41:2231-8. [PMID: 31564514 DOI: 10.1016/j.clinthera.2019.08.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
33 Li Z, Dumas T, Seth Berry N, McCoy B, Yel L. Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases. Int Immunopharmacol 2021;100:108044. [PMID: 34601202 DOI: 10.1016/j.intimp.2021.108044] [Reference Citation Analysis]
34 Velay A, Solis M, Benotmane I, Gantner P, Soulier E, Moulin B, Caillard S, Fafi-Kremer S. Intravenous Immunoglobulin Administration Significantly Increases BKPyV Genotype-Specific Neutralizing Antibody Titers in Kidney Transplant Recipients. Antimicrob Agents Chemother 2019;63:e00393-19. [PMID: 31160292 DOI: 10.1128/AAC.00393-19] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
35 Perricone C, Triggianese P, Bursi R, Cafaro G, Bartoloni E, Chimenti MS, Gerli R, Perricone R. Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections. Microorganisms 2021;9:121. [PMID: 33430200 DOI: 10.3390/microorganisms9010121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
36 Seria E, Samut Tagliaferro S, Cutajar D, Galdies R, Felice A. Immunoglobulin G in Platelet-Derived Wound Healing Factors. Biomed Res Int 2021;2021:4762657. [PMID: 33575328 DOI: 10.1155/2021/4762657] [Reference Citation Analysis]
37 McAlpine SM, Roberts SE, Heath JJ, Käsermann F, Issekutz AC, Issekutz TB, Derfalvi B. High Dose Intravenous IgG Therapy Modulates Multiple NK Cell and T Cell Functions in Patients With Immune Dysregulation. Front Immunol 2021;12:660506. [PMID: 34093549 DOI: 10.3389/fimmu.2021.660506] [Reference Citation Analysis]
38 Lew J, Casey M, Leard LE, Hays S, Otani IM. Perceptions Around Lung Transplant-Associated Hypogammaglobulinemia. J Clin Immunol 2021. [PMID: 34351551 DOI: 10.1007/s10875-021-01111-6] [Reference Citation Analysis]
39 Melo KM, Alves LM, Valente CFC, Tavares FS. One-year intravenous immunoglobulin replacement therapy: efficacy in reducing hospital admissions in pediatric patients with Inborn Errors of Immunity. J Pediatr (Rio J) 2021:S0021-7557(21)00096-6. [PMID: 34273274 DOI: 10.1016/j.jped.2021.05.011] [Reference Citation Analysis]
40 Dubey S, Heinen S, Krantic S, McLaurin J, Branch DR, Hynynen K, Aubert I. Clinically approved IVIg delivered to the hippocampus with focused ultrasound promotes neurogenesis in a model of Alzheimer's disease. Proc Natl Acad Sci U S A 2020;117:32691-700. [PMID: 33288687 DOI: 10.1073/pnas.1908658117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
41 Wang S, Bai M, Xu K, Shao Y, Yang Z, Xiong X, Huang R, Li Y, Liu H. Effects of Coated Cysteamine on Oxidative Stress and Inflammation in Weaned Pigs. Animals (Basel) 2021;11:2217. [PMID: 34438677 DOI: 10.3390/ani11082217] [Reference Citation Analysis]
42 Farini A, Villa C, Tripodi L, Legato M, Torrente Y. Role of Immunoglobulins in Muscular Dystrophies and Inflammatory Myopathies. Front Immunol 2021;12:666879. [PMID: 34335568 DOI: 10.3389/fimmu.2021.666879] [Reference Citation Analysis]
43 Wall DA, Krueger J. Chimeric antigen receptor T cell therapy comes to clinical practice. Curr Oncol 2020;27:S115-23. [PMID: 32368181 DOI: 10.3747/co.27.5283] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
44 Linares NA, Bouchard M, Gutiérrez NS, Colmenares M, Cantor-Garcia A, Gabaldon-Figueira JC, Bellorin AV, Rujano B, Peterson DL, Salmen S. Immunological features in pediatric patients with recurrent and severe infection: Identification of Primary Immunodeficiency Diseases in Merida, Venezuela. Allergol Immunopathol (Madr) 2019;47:437-48. [PMID: 31371133 DOI: 10.1016/j.aller.2019.02.002] [Reference Citation Analysis]
45 Alsaleem M. Intravenous Immune Globulin Uses in the Fetus and Neonate: A Review. Antibodies (Basel) 2020;9:E60. [PMID: 33158209 DOI: 10.3390/antib9040060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Stanciu AE, Popescu M, Gheorghe DC. Idiotype-specific intravenous immunoglobulin for therapy of immunoglobulin kappa free light chain deficiency. Hum Vaccin Immunother 2019;15:1123-5. [PMID: 30676854 DOI: 10.1080/21645515.2019.1572411] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
47 Jacobs J, Kneib J, Gabbard A. Intravenous Immunoglobulin-Associated Hemolytic Anemia. Lab Med 2020;51:e47-50. [PMID: 32339244 DOI: 10.1093/labmed/lmaa019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Raman RS, Bhagwan Barge V, Anil Kumar D, Dandu H, Rakesh Kartha R, Bafna V, Aravinda VT, Raghuram TC. A Phase II Safety and Efficacy Study on Prognosis of Moderate Pneumonia in Coronavirus Disease 2019 Patients With Regular Intravenous Immunoglobulin Therapy. J Infect Dis 2021;223:1538-43. [PMID: 33585890 DOI: 10.1093/infdis/jiab098] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
49 Tölle M, Freitag H, Antelmann M, Hartwig J, Schuchardt M, van der Giet M, Eckardt KU, Grabowski P, Scheibenbogen C. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat Immunoadsorption. J Clin Med 2020;9:E2443. [PMID: 32751659 DOI: 10.3390/jcm9082443] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
50 Fu Z, Zhou J, Chen R, Jin Y, Ni T, Qian L, Xiao C. Cluster of differentiation 19 chimeric antigen receptor T-cell therapy in pediatric acute lymphoblastic leukemia. Oncol Lett 2020;20:36. [PMID: 32802160 DOI: 10.3892/ol.2020.11897] [Reference Citation Analysis]
51 Meckley LM, Wu Y, Ito D, Berner T, McCoy B, Yel L. Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials. BMC Immunol 2020;21:24. [PMID: 32366233 DOI: 10.1186/s12865-020-00346-z] [Reference Citation Analysis]
52 Peppers BP, Zacharias J, Michaud CR, Frith JA, Varma P, Henning M, Quinn LM, Tcheurekdjian H, Craig T, Hostoffer RW. Association between α1-antitrypsin and bronchiectasis in patients with humoral immunodeficiency receiving gammaglobulin infusions. Ann Allergy Asthma Immunol 2018;120:200-6. [PMID: 29413345 DOI: 10.1016/j.anai.2017.11.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
53 Lacombe V, Nunes Gomes C, Robin JB, Thépot S, François S, Cottin L, Ugo V, Dieu X, Abgueguen P, Daniel V, Giltat A, Hunault M, Riou J, Orvain C, Schmidt A. Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations. Eur J Haematol 2021. [PMID: 34245060 DOI: 10.1111/ejh.13686] [Reference Citation Analysis]
54 Kim BH, Lee S. Sophoricoside from Styphnolobium japonicum improves experimental atopic dermatitis in mice. Phytomedicine 2021;82:153463. [PMID: 33545490 DOI: 10.1016/j.phymed.2021.153463] [Reference Citation Analysis]
55 McShane PJ. Common Variable Immunodeficiency and Other Immunodeficiency Syndromes in Bronchiectasis. Semin Respir Crit Care Med 2021;42:525-36. [PMID: 34261177 DOI: 10.1055/s-0041-1730893] [Reference Citation Analysis]
56 [DOI: 10.1101/2020.07.20.20157891] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
57 Serra A, Marzo N, Pons B, Maduell P, López M, Grancha S. Characterization of antibodies in human immunoglobulin products from different regions worldwide. Int J Infect Dis 2021;104:610-6. [PMID: 33524620 DOI: 10.1016/j.ijid.2021.01.034] [Reference Citation Analysis]
58 Saha C, Kothapalli P, Patil V, ManjunathaReddy GB, Kaveri SV, Bayry J. Intravenous immunoglobulin suppresses the polarization of both classically and alternatively activated macrophages. Hum Vaccin Immunother 2020;16:233-9. [PMID: 30945973 DOI: 10.1080/21645515.2019.1602434] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Stump SE, Schepers AJ, Jones AR, Alexander MD, Auten JJ. Comparison of Weight-Based Dosing Strategies for Intravenous Immunoglobulin in Patients with Hematologic Malignancies. Pharmacotherapy 2017;37:1530-6. [DOI: 10.1002/phar.2047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
60 Ciobanu AM, Dumitru AE, Gica N, Botezatu R, Peltecu G, Panaitescu AM. Benefits and Risks of IgG Transplacental Transfer. Diagnostics (Basel) 2020;10:E583. [PMID: 32806663 DOI: 10.3390/diagnostics10080583] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
61 Qi T, Cao Y. In Translation: FcRn across the Therapeutic Spectrum. Int J Mol Sci 2021;22:3048. [PMID: 33802650 DOI: 10.3390/ijms22063048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Almontasheri A, Al-Husayni F, Alsuraihi AK, Binyahib H, Albanna AS. The Clinical Course of COVID-19 Pneumonia in a 19-Year-Old Man on Intravenous Immunoglobulin Replacement Therapy for X-Linked Agammaglobulinemia. Am J Case Rep 2021;22:e929447. [PMID: 33612712 DOI: 10.12659/AJCR.929447] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
63 Lion J, Burbach M, Cross A, Poussin K, Taflin C, Kaveri S, Haziot A, Glotz D, Mooney N. Endothelial Cell Amplification of Regulatory T Cells Is Differentially Modified by Immunosuppressors and Intravenous Immunoglobulin. Front Immunol. 2017;8:1761. [PMID: 29312302 DOI: 10.3389/fimmu.2017.01761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
64 Sun P, Zhang W, Du X, Zhu L, Xu J, Cheng L, Zhou X, Shi Z, Liu Y, Xie T, Liao Z, Qin LJ, Zhang P, Su W, Zhang X, Lu Y, Wei Q, Liu B, Liu F, Li C, Ye S, Zhang Y, Ma L. Demographic Characteristics and Lifestyle Habits of Chinese Plasma Donors: A Multicenter Study. Med Sci Monit 2021;27:e931471. [PMID: 34446688 DOI: 10.12659/MSM.931471] [Reference Citation Analysis]
65 Walter G, Kalicinsky C, Warrington R, Miguel M, Reyes J, Rubin TS. Delivery of subcutaneous immunoglobulin by rapid "push" infusion for primary immunodeficiency patients in Manitoba: a retrospective review. Allergy Asthma Clin Immunol 2020;16:34. [PMID: 32426003 DOI: 10.1186/s13223-020-00431-3] [Reference Citation Analysis]
66 Leiding JW, Forbes LR. Mechanism-Based Precision Therapy for the Treatment of Primary Immunodeficiency and Primary Immunodysregulatory Diseases. The Journal of Allergy and Clinical Immunology: In Practice 2019;7:761-73. [DOI: 10.1016/j.jaip.2018.12.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
67 Suresh J, Kyle BD. Clinical false positives resulting from recent intravenous immunoglobulin therapy: case report. BMC Infect Dis 2021;21:288. [PMID: 33743628 DOI: 10.1186/s12879-021-05986-z] [Reference Citation Analysis]
68 Wilmot HV, Gray E. Enabling accurate measurement of activated factor XI (FXIa) in therapeutic immunoglobulin products. Vox Sang 2021;116:656-64. [PMID: 33277936 DOI: 10.1111/vox.13046] [Reference Citation Analysis]
69 Wijetilleka S, Jayne DR, Mukhtyar C, Ala A, Bright PD, Chinoy H, Harper L, Kazmi MA, Kiani-Alikhan S, Li CK, Misbah SA, Oni L, Price-Kuehne FE, Salama AD, Workman S, Wrench D, Karim MY. Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. Rheumatology (Oxford) 2019;58:889-96. [PMID: 30590695 DOI: 10.1093/rheumatology/key394] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
70 Edington HJ, Sutton KS, Bennett C, Chandrakasan S, Sterner-Allison J, Castellino SM. Dealing with a critical national shortage-Approaches to triaging immune globulin supply in pediatric hematology and oncology. Pediatr Blood Cancer 2020;67:e28260. [PMID: 32329568 DOI: 10.1002/pbc.28260] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
71 Blum AE, Burgin S. Eczematous Drug Eruptions. Am J Clin Dermatol 2021;22:349-66. [PMID: 33587283 DOI: 10.1007/s40257-021-00586-8] [Reference Citation Analysis]
72 Alotaibi NM, Filho FSL, Mattman A, Hollander Z, Chen V, Ng R, Leung JM, Sin DD. IgG Levels and Mortality in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2021;204:362-5. [PMID: 33945775 DOI: 10.1164/rccm.202102-0382LE] [Reference Citation Analysis]
73 Filion CA, Taylor-Black S, Maglione PJ, Radigan L, Cunningham-Rundles C. Differentiation of Common Variable Immunodeficiency From IgG Deficiency. J Allergy Clin Immunol Pract 2019;7:1277-84. [PMID: 30557717 DOI: 10.1016/j.jaip.2018.12.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
74 Kitt E, Hayes M, Cárdenas AM, Green AM. Interpretation and management of positive anti-hepatitis B core antibody tests in immunocompromised pediatric patients. Transpl Infect Dis 2019;21:e13074. [PMID: 30868720 DOI: 10.1111/tid.13074] [Reference Citation Analysis]
75 Cuadrado MJ, Calatayud I, Urquizu-Padilla M, Wijetilleka S, Kiani-Alikhan S, Karim MY. Immunoglobulin abnormalities are frequent in patients with lupus nephritis. BMC Rheumatol 2019;3:30. [PMID: 31453435 DOI: 10.1186/s41927-019-0079-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
76 Yang C, Huang Y, Liu S. Therapeutic Development in COVID-19. Adv Exp Med Biol 2021;1318:435-48. [PMID: 33973193 DOI: 10.1007/978-3-030-63761-3_25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Sala TP, Crave JC, Duracinsky M, Lepira Bompeka F, Tadmouri A, Chassany O, Cherin P. Efficacy and patient satisfaction in the use of subcutaneous immunoglobulin immunotherapy for the treatment of auto-immune neuromuscular diseases. Autoimmun Rev 2018;17:873-81. [PMID: 30005853 DOI: 10.1016/j.autrev.2018.03.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
78 Benbrahim O, Viallard J, Choquet S, Royer B, Bauduer F, Decaux O, Crave J, Fardini Y, Clerson P, Lévy V. The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments. Hematology 2019;24:173-82. [DOI: 10.1080/10245332.2018.1538001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
79 Menon D, Sarpong E, Bril V. Practical Aspects of Transitioning from Intravenous to Subcutaneous Immunoglobulin Therapy in Neuromuscular Disorders. Can J Neurol Sci 2021;:1-7. [PMID: 33766159 DOI: 10.1017/cjn.2021.56] [Reference Citation Analysis]
80 Cen SY, Branch DR. Isoagglutinin-reduced immunoglobulin retains efficacy in mouse models of immune thrombocytopenia and rheumatoid arthritis and is less likely to cause intravenous immunoglobulin-associated hemolysis. Transfusion 2020;60:250-5. [PMID: 31837028 DOI: 10.1111/trf.15622] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
81 Cicco S, Cicco G, Racanelli V, Vacca A. Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment. Mediators Inflamm 2020;2020:7527953. [PMID: 32724296 DOI: 10.1155/2020/7527953] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 22.0] [Reference Citation Analysis]
82 Edgar JDM, Richter AG, Huissoon AP, Kumararatne DS, Baxendale HE, Bethune CA, Garcez T, Misbah SA, Sorensen RU; United Kingdom Primary Immunodeficiency Network (UKPIN) Immunoglobulin Decision to Treat Study Group. Prescribing Immunoglobulin Replacement Therapy for Patients with Non-classical and Secondary Antibody Deficiency: an Analysis of the Practice of Clinical Immunologists in the UK and Republic of Ireland. J Clin Immunol 2018;38:204-13. [PMID: 29423883 DOI: 10.1007/s10875-017-0469-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
83 Emre S. Intravenous immunoglobulin treatment: Where do dermatologists stand? Dermatol Ther 2019;32:e12854. [PMID: 30756448 DOI: 10.1111/dth.12854] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Manaresi E, Gallinella G. Advances in the Development of Antiviral Strategies against Parvovirus B19. Viruses 2019;11:E659. [PMID: 31323869 DOI: 10.3390/v11070659] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
85 Rairikar M, Kazi ZB, Desai A, Walters C, Rosenberg A, Kishnani PS. High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient. Mol Genet Metab 2017;122:76-9. [PMID: 28648664 DOI: 10.1016/j.ymgme.2017.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
86 Hassin O, Abu Freih Y, Hazan R, Lev A, Zrihen KS, Somech R, Broides A, Nahum A. Trough Concentrations of Specific Antibodies in Primary Immunodeficiency Patients Receiving Intravenous Immunoglobulin Replacement Therapy. J Clin Med 2021;10:592. [PMID: 33557365 DOI: 10.3390/jcm10040592] [Reference Citation Analysis]
87 França TT, Barreiros LA, Al-Ramadi BK, Ochs HD, Cabral-Marques O, Condino-Neto A. CD40 ligand deficiency: treatment strategies and novel therapeutic perspectives. Expert Rev Clin Immunol 2019;15:529-40. [PMID: 30681380 DOI: 10.1080/1744666X.2019.1573674] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
88 Melamed IR, Miranda H, Heffron M, Harper JR. Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study. Front Immunol 2021;12:632744. [PMID: 33737935 DOI: 10.3389/fimmu.2021.632744] [Reference Citation Analysis]
89 Xiang HR, Cheng X, Li Y, Luo WW, Zhang QZ, Peng WX. Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): A meta-analysis. Int Immunopharmacol 2021;96:107732. [PMID: 34162133 DOI: 10.1016/j.intimp.2021.107732] [Reference Citation Analysis]
90 Arnold DE, Maude SL, Callahan CA, DiNofia AM, Grupp SA, Heimall JR. Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients. Pediatr Blood Cancer 2020;67:e28092. [PMID: 31793170 DOI: 10.1002/pbc.28092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
91 Wasserman RL. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. Immunotherapy 2017;9:1035-50. [DOI: 10.2217/imt-2017-0092] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
92 Almaghlouth I, Su J, Johnson SR, Pullenayegum E, Gladman D, Urowitz M. Acquired low immunoglobulin levels and risk of clinically relevant infection in adult patients with systemic lupus erythematosus: a cohort study. Rheumatology (Oxford) 2021;60:1456-64. [PMID: 33006611 DOI: 10.1093/rheumatology/keaa641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
93 Stonebraker JS, Hajjar J, Orange JS. Latent therapeutic demand model for the immunoglobulin replacement therapy of primary immune deficiency disorders in the USA. Vox Sang 2018;113:430-40. [DOI: 10.1111/vox.12651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
94 Canessa C, Gallo V, Pignata C, Trizzino A, Graziani S, Martire B, Moschese V, Palladino V, Boggia GM, Matucci A, Pecoraro A, Spadaro G, Vultaggio A, Azzari C. Subcutaneous Immunoglobulin Twenty Percent Every Two Weeks in Pediatric Patients with Primary Immunodeficiencies: Subcohort Analysis of the IBIS Study. Pediatr Allergy Immunol Pulmonol 2019;32:70-5. [PMID: 31508259 DOI: 10.1089/ped.2018.0967] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
95 Hanitsch L, Baumann U, Boztug K, Burkhard-Meier U, Fasshauer M, Habermehl P, Hauck F, Klock G, Liese J, Meyer O, Müller R, Pachlopnik-Schmid J, Pfeiffer-Kascha D, Warnatz K, Wehr C, Wittke K, Niehues T, von Bernuth H. Treatment and management of primary antibody deficiency: German interdisciplinary evidence-based consensus guideline. Eur J Immunol 2020;50:1432-46. [PMID: 32845010 DOI: 10.1002/eji.202048713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
96 Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, Vankerckhoven B, Verheesen P, Ongenae N, Lykhopiy V, Enriquez FJ, Cho J, Ober RJ, Ward ES, de Haard H, Leupin N. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest 2018;128:4372-86. [PMID: 30040076 DOI: 10.1172/JCI97911] [Cited by in Crossref: 65] [Cited by in F6Publishing: 37] [Article Influence: 16.3] [Reference Citation Analysis]
97 Fisher J, Linder A, Calevo MG, Bentzer P. Non-corticosteroid adjuvant therapies for acute bacterial meningitis. Cochrane Database Syst Rev 2021;11:CD013437. [PMID: 34813078 DOI: 10.1002/14651858.CD013437.pub2] [Reference Citation Analysis]
98 Lopez-Sanz L, Bernal S, Jimenez-Castilla L, Prieto I, La Manna S, Gomez-Lopez S, Blanco-Colio LM, Egido J, Martin-Ventura JL, Gomez-Guerrero C. Fcγ receptor activation mediates vascular inflammation and abdominal aortic aneurysm development. Clin Transl Med 2021;11:e463. [PMID: 34323424 DOI: 10.1002/ctm2.463] [Reference Citation Analysis]
99 N'kaoua E, Attarian S, Delmont E, Campana-Salort E, Verschueren A, Grapperon AM, Mestivier E, Roche M. Immunoglobulin shortage: Practice modifications and clinical outcomes in a reference centre. Rev Neurol (Paris) 2021:S0035-3787(21)00768-2. [PMID: 34872746 DOI: 10.1016/j.neurol.2021.10.004] [Reference Citation Analysis]
100 Li D, Lou Y, Zhang Y, Liu S, Li J, Tao J. Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases. Theranostics 2021;11:5430-46. [PMID: 33859756 DOI: 10.7150/thno.53961] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Fakhari Z, Farsaei S, Sabzghabaee AM. Predicting Factors for the Pattern of Intravenous Immunoglobulin Utilization in a Middle Eastern University Hospital. J Res Pharm Pract 2018;7:188-94. [PMID: 30622986 DOI: 10.4103/jrpp.JRPP_18_73] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
102 Prete M, Favoino E, Catacchio G, Racanelli V, Perosa F. SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? Autoimmun Rev 2020;19:102559. [PMID: 32361195 DOI: 10.1016/j.autrev.2020.102559] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
103 Sorensen RU, Edgar D. Specific Antibody Deficiencies in Clinical Practice. J Allergy Clin Immunol Pract 2019;7:801-8. [PMID: 30682575 DOI: 10.1016/j.jaip.2019.01.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
104 Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, Steiner ME, Cheifetz IM, Lehmann LE, Mejia R, Slopis JM, Bajwa R, Kebriaei P, Martin PL, Moffet J, McArthur J, Petropoulos D, O'Hanlon Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol 2019;16:45-63. [PMID: 30082906 DOI: 10.1038/s41571-018-0075-2] [Cited by in Crossref: 90] [Cited by in F6Publishing: 86] [Article Influence: 30.0] [Reference Citation Analysis]
105 Nair PM, Rendo MJ, Reddoch-Cardenas KM, Burris JK, Meledeo MA, Cap AP. Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease. Semin Hematol 2020;57:73-82. [PMID: 32892846 DOI: 10.1053/j.seminhematol.2020.07.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
106 Wahn V, von Bernuth H. IgG subclass deficiencies in children: Facts and fiction. Pediatr Allergy Immunol 2017;28:521-4. [PMID: 28686792 DOI: 10.1111/pai.12757] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
107 Hsu LI, Chen JW, Lin DT, Hung YS, Hou SM. Clinical use of intravenous immunoglobulin in Taiwan: A 10-year population study. J Formos Med Assoc 2021;120:1921-5. [PMID: 33726936 DOI: 10.1016/j.jfma.2021.02.017] [Reference Citation Analysis]
108 Li Z, McCoy B, Engl W, Yel L. Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin. J Clin Immunol 2021;41:1331-8. [PMID: 34036490 DOI: 10.1007/s10875-021-00990-z] [Reference Citation Analysis]
109 Orino K. Binding of Immunoglobulin G to Protoporphyrin IX and Its Derivatives: Evidence the Fab Domain Recognizes the Protoporphyrin Ring. Antibodies (Basel) 2019;8:E6. [PMID: 31544812 DOI: 10.3390/antib8010006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
110 Hémar V, Rivière E, Greib C, Machelart I, Roucoules M, Prot C, Pellegrin JL, Viallard JF, Lazaro E. A summertime pause in immunoglobulin replacement therapy: a prospective real-world analysis. Immunotherapy 2021;13:1491-9. [PMID: 34743547 DOI: 10.2217/imt-2020-0313] [Reference Citation Analysis]
111 Restivo JS, Karafin MS. Human Immunoglobulin Preparations. Transfusion Medicine and Hemostasis. Elsevier; 2019. pp. 235-46. [DOI: 10.1016/b978-0-12-813726-0.00039-8] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 Chen X, Hu Mt W, Yang M, Ling J, Zhang Y, Deng L, Li J, Lundkvist Å, Lindahl JF, Xiong Y. Risk factors for the delayed viral clearance in COVID-19 patients. J Clin Hypertens (Greenwich) 2021;23:1483-9. [PMID: 34171164 DOI: 10.1111/jch.14308] [Reference Citation Analysis]
113 Rambabu N, Mathew MJ, Kaveri SV, Bayry J. Boolean analysis of the transcriptomic data to identify novel biomarkers of IVIG response. Autoimmun Rev 2021;20:102850. [PMID: 33971345 DOI: 10.1016/j.autrev.2021.102850] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
114 Khan F, Person H, Dekio F, Ogawa M, Ho HE, Dunkin D, Secord E, Cunningham-Rundles C, Ward SC. Crohn's-like Enteritis in X-Linked Agammaglobulinemia: A Case Series and Systematic Review. J Allergy Clin Immunol Pract 2021:S2213-2198(21)00579-1. [PMID: 34029777 DOI: 10.1016/j.jaip.2021.04.070] [Reference Citation Analysis]
115 Gupta S, Stein M, Hussain I, Paris K, Engl W, McCoy B, Rabbat CJ, Yel L. Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases. Ann Allergy Asthma Immunol 2019;123:271-279.e1. [PMID: 31228628 DOI: 10.1016/j.anai.2019.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Varadé J, Magadán S, González-Fernández Á. Human immunology and immunotherapy: main achievements and challenges. Cell Mol Immunol 2021;18:805-28. [PMID: 32879472 DOI: 10.1038/s41423-020-00530-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
117 Pedini V, Verga JU, Terrenato I, Menghini D, Mezzanotte C, Danieli MG. Incidence of malignancy in patients with common variable immunodeficiency according to therapeutic delay: an Italian retrospective, monocentric cohort study. Allergy Asthma Clin Immunol 2020;16:54. [PMID: 32944022 DOI: 10.1186/s13223-020-00451-z] [Reference Citation Analysis]
118 Gupton SE, McCarthy EA, Markert ML. Care of Children with DiGeorge Before and After Cultured Thymus Tissue Implantation. J Clin Immunol 2021;41:896-905. [PMID: 34003433 DOI: 10.1007/s10875-021-01044-0] [Reference Citation Analysis]
119 Nowacka-Cieciura E, Karakulska-Prystupiuk E, Żuk-Wasek A, Lisik W, Basak GW, Durlik M. Pure Red Cell Aplasia Related to Parvovirus B19 Infection in Simultaneous Pancreas and Kidney Recipient: A Case Report. Transplant Proc 2020;52:2539-43. [PMID: 32591136 DOI: 10.1016/j.transproceed.2020.01.127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn SJ, Floto AR, Grillo L, Gruffydd-Jones K, Harvey A, Haworth CS, Hiscocks E, Hurst JR, Johnson C, Kelleher PW, Bedi P, Payne K, Saleh H, Screaton NJ, Smith M, Tunney M, Whitters D, Wilson R, Loebinger MR. British Thoracic Society Guideline for bronchiectasis in adults. Thorax 2019;74:1-69. [PMID: 30545985 DOI: 10.1136/thoraxjnl-2018-212463] [Cited by in Crossref: 89] [Cited by in F6Publishing: 90] [Article Influence: 29.7] [Reference Citation Analysis]
121 Dumas T, Berry NS, Wolfsegger M, Jolles S, Mccoy B, Yel L. Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases. International Immunopharmacology 2019;71:404-10. [DOI: 10.1016/j.intimp.2019.03.034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
122 Teh BW, Tam CS, Handunnetti S, Worth LJ, Slavin MA. Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies. Blood Reviews 2018;32:499-507. [DOI: 10.1016/j.blre.2018.04.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
123 Xie B, Zhang J, Li Y, Yuan S, Shang Y. COVID-19: Imbalanced Immune Responses and Potential Immunotherapies. Front Immunol 2020;11:607583. [PMID: 33584679 DOI: 10.3389/fimmu.2020.607583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
124 Sleasman JW, Lumry WR, Hussain I, Wedner HJ, Harris JB, Courtney KL, Mondou E, Lin J, Stein MR. Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study. Immunotherapy 2019;11:1371-86. [PMID: 31621458 DOI: 10.2217/imt-2019-0159] [Reference Citation Analysis]
125 Karmakar D, Lahiri B, Ranjan P, Chatterjee J, Lahiri P, Sengupta S. Road Map to Understanding SARS-CoV-2 Clinico-Immunopathology and COVID-19 Disease Severity. Pathogens 2020;10:5. [PMID: 33374748 DOI: 10.3390/pathogens10010005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
126 Mallick R, Divino V, Smith BD, Jolles S, DeKoven M, Vinh DC. Infections in secondary immunodeficiency patients treated with Privigen® or Hizentra®: a retrospective US administrative claims study in patients with hematological malignancies. Leuk Lymphoma 2021;:1-11. [PMID: 34569910 DOI: 10.1080/10428194.2021.1961233] [Reference Citation Analysis]
127 Vrettou CS, Vassiliou AG, Kakkas I, Jahaj E, Tsipilis S, Athanasiou N, Zacharis A, Keskinidou C, Papageorgiou A, Orfanos SE, Kotanidou A, Dimopoulou I. Low Admission Immunoglobulin G Levels Predict Poor Outcome in Patients with Mild-to-Critical COVID-19: A Prospective, Single-Center Study. J Epidemiol Glob Health 2021. [PMID: 34734379 DOI: 10.1007/s44197-021-00002-8] [Reference Citation Analysis]
128 Hayashi T, Hayashi A, Fujimura Y, Masaki M, Kishikawa T, Sakaguchi H, Tanaka M, Kimura T, Tani Y, Takihara Y, Hirayama F. Dual preparation of plasma and platelet concentrates in platelet additive solution from platelet concentrates in plasma using a novel filtration system. Vox Sang 2021. [PMID: 34082471 DOI: 10.1111/vox.13155] [Reference Citation Analysis]
129 Ricci S, Lippi F, Canessa C, Guarnieri C, Macchia R, Azzari C. Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency. Int J Immunopathol Pharmacol 2020;34:2058738420943006. [PMID: 32924667 DOI: 10.1177/2058738420943006] [Reference Citation Analysis]
130 Patel DD, Bussel JB. Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention. J Allergy Clin Immunol 2020;146:467-78. [PMID: 32896307 DOI: 10.1016/j.jaci.2020.07.015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
131 Diep C, Shih AW, Jamula E, Heddle NM, Parvizian M, Hillis CM. Impact of organizational interventions on reducing inappropriate intravenous immunoglobulin (IVIG) usage: A systematic review and meta-analysis. Transfus Apher Sci 2018;57:215-21. [PMID: 29439921 DOI: 10.1016/j.transci.2018.01.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
132 Hill JA, Giralt S, Torgerson TR, Lazarus HM. CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Rev 2019;38:100596. [PMID: 31416717 DOI: 10.1016/j.blre.2019.100596] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
133 Galeotti C, Stephen-Victor E, Karnam A, Das M, Gilardin L, Maddur MS, Wymann S, Vonarburg C, Chevailler A, Dimitrov JD, Benveniste O, Bruhns P, Kaveri SV, Bayry J. Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE. J Allergy Clin Immunol 2019;144:524-535.e8. [PMID: 30529242 DOI: 10.1016/j.jaci.2018.10.064] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
134 Ali HS, Elshafei MS, Saad MO, Mitwally HA, Al Wraidat M, Aroos A, Shaikh N, Ananthegowda DC, Abdelaty MA, George S, Nashwan AJ, Mohamed AS, Khatib MY. Clinical outcomes of intravenous immunoglobulin therapy in COVID-19 related acute respiratory distress syndrome: a retrospective cohort study. BMC Pulm Med 2021;21:354. [PMID: 34743710 DOI: 10.1186/s12890-021-01717-x] [Reference Citation Analysis]
135 Ye C, Liu J, Song X, Zheng S, Liu J. A clinician survey for management of the secondary immunodeficiency caused by hematological malignancies in China. Medicine (Baltimore) 2021;100:e23935. [PMID: 33545966 DOI: 10.1097/MD.0000000000023935] [Reference Citation Analysis]
136 Scheibenbogen C, Sotzny F, Hartwig J, Bauer S, Freitag H, Wittke K, Doehner W, Scherbakov N, Loebel M, Grabowski P. Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study. J Clin Med 2021;10:2420. [PMID: 34072494 DOI: 10.3390/jcm10112420] [Reference Citation Analysis]
137 Dougherty JA, Yarsley RL. Intravenous Immune Globulin (IVIG) for Treatment of Autoimmune Heparin-Induced Thrombocytopenia: A Systematic Review. Ann Pharmacother 2021;55:198-215. [PMID: 32693627 DOI: 10.1177/1060028020943542] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
138 Hanson KE, Gabriel N, Mchardy I, Hoffmann W, Cohen SH, Couturier MR, Thompson GR 3rd. Impact of IVIG therapy on serologic testing for infectious diseases. Diagn Microbiol Infect Dis 2020;96:114952. [PMID: 31787407 DOI: 10.1016/j.diagmicrobio.2019.114952] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
139 Gernez Y, Baker MG, Maglione PJ. Humoral immunodeficiencies: conferred risk of infections and benefits of immunoglobulin replacement therapy. Transfusion 2018;58 Suppl 3:3056-64. [PMID: 30536429 DOI: 10.1111/trf.15020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
140 Jahnz-RÓŻyk K, WiĘsik-Szewczyk E, RoliŃski J, Siedlar M, JĘdrzejczak W, Sydor W, Tomaszewska A. Secondary immunodeficiencies with predominant antibody deficiency: multidisciplinary perspectives of Polish experts. Cent Eur J Immunol 2020;45:334-41. [PMID: 33437186 DOI: 10.5114/ceji.2020.101265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
141 Beecher G, Anderson D, Siddiqi ZA. Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial. Neurology 2017;89:1135-41. [PMID: 28814461 DOI: 10.1212/WNL.0000000000004365] [Cited by in Crossref: 27] [Cited by in F6Publishing: 3] [Article Influence: 5.4] [Reference Citation Analysis]
142 Miranda D, Bulger EM. Novel Immune Therapies in the Management of Streptococcal Sepsis and Necrotizing Soft Tissue Infections. Surgical Infections 2018;19:745-9. [DOI: 10.1089/sur.2018.225] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 Branch DR, Hellberg Å, Bruggeman CW, Storry JR, Sakac D, Blacquiere M, Tong TN, Burke-Murphy E, Binnington B, Parmar N, Riden LS, Willie K, Armali C, Aziz J, Lieberman L, Laroche V, Callum J, Lin Y, Shehata N, Pavenski K, Lau W, Hannach B, Kuijpers TW, Olsson ML, Cserti-Gazdewich C, Pendergrast J. ABO zygosity, but not secretor or Fc receptor status, is a significant risk factor for IVIG-associated hemolysis. Blood 2018;131:830-5. [PMID: 29305554 DOI: 10.1182/blood-2017-07-796151] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
144 Yasuda N, Nishikawa M, Shimosaka H, Ono Y, Yatomi Y. Effect of administration of immunoglobulin preparations on the results of tests for autoantibodies. Mod Rheumatol 2021:roab085. [PMID: 34918126 DOI: 10.1093/mr/roab085] [Reference Citation Analysis]
145 Cordero E, Goycochea-Valdivia W, Mendez-Echevarria A, Allende LM, Alsina L, Bravo García-Morato M, Gil-Herrera J, Gudiol C, Len-Abad O, López-Medrano F, Moreno-Pérez D, Muñoz P, Olbrich P, Sánchez-Ramón S, Soler-Palacín P, Aguilera Cros C, Arostegui JI, Badell Serra I, Carbone J, Fortún J, Gonzalez-Granado LI, López-Granados E, Lucena JM, Parody R, Ramakers J, Regueiro JR, Rivière JG, Roca-Oporto C, Rodríguez Pena R, Santos-Pérez JL, Rodríguez-Gallego C, Neth O. Executive Summary of the Consensus Document on the Diagnosis and Management of Patients with Primary Immunodeficiencies. Enferm Infecc Microbiol Clin (Engl Ed) 2020;38:438-43. [PMID: 33161954 DOI: 10.1016/j.eimc.2020.07.001] [Reference Citation Analysis]
146 Kafal AR, Vinh DC, Langelier MJ. Prefilled syringes for immunoglobulin G (IgG) replacement therapy: clinical experience from other disease settings. Expert Opinion on Drug Delivery 2018;15:1199-209. [DOI: 10.1080/17425247.2018.1546692] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
147 Karnam A, Rambabu N, Das M, Bou-Jaoudeh M, Delignat S, Käsermann F, Lacroix-Desmazes S, Kaveri SV, Bayry J. Therapeutic normal IgG intravenous immunoglobulin activates Wnt-β-catenin pathway in dendritic cells. Commun Biol 2020;3:96. [PMID: 32132640 DOI: 10.1038/s42003-020-0825-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
148 Cao H, Du X, Zeng R, Lv Z, Ye S, Jiang P, Wang Z, Ma L, Huang Y, Li C, Zhang R, Liu F. Effect of Different Aβ Aggregates as Antigen on the Measure of Naturally Occurring Autoantibodies against Amyloid-β40/42 in IVIG. Curr Alzheimer Res 2019;16:1290-9. [PMID: 31894747 DOI: 10.2174/1567205017666200102151731] [Reference Citation Analysis]
149 Sorensen RU. A Critical View of Specific Antibody Deficiencies. Front Immunol 2019;10:986. [PMID: 31118939 DOI: 10.3389/fimmu.2019.00986] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
150 Ye C, Chen W, Gao Q, Chen Y, Song X, Zheng S, Liu J. Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of <5 g/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China. Med Sci Monit 2021;27:e930241. [PMID: 34238914 DOI: 10.12659/MSM.930241] [Reference Citation Analysis]
151 Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward. Front Immunol 2021;12:765097. [PMID: 34777381 DOI: 10.3389/fimmu.2021.765097] [Reference Citation Analysis]
152 Callery EL, Morais CLM, Paraskevaidi M, Brusic V, Vijayadurai P, Anantharachagan A, Martin FL, Rowbottom AW. New approach to investigate Common Variable Immunodeficiency patients using spectrochemical analysis of blood. Sci Rep 2019;9:7239. [PMID: 31076587 DOI: 10.1038/s41598-019-43196-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
153 Maddur MS, Lacroix-Desmazes S, Dimitrov JD, Kazatchkine MD, Bayry J, Kaveri SV. Natural Antibodies: from First-Line Defense Against Pathogens to Perpetual Immune Homeostasis. Clin Rev Allergy Immunol 2020;58:213-28. [PMID: 31161341 DOI: 10.1007/s12016-019-08746-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
154 Smits BM, Kleine Budde I, de Vries E, Ten Berge IJM, Bredius RGM, van Deuren M, van Dissel JT, Ellerbroek PM, van der Flier M, van Hagen PM, Nieuwhof C, Rutgers B, Sanders LEAM, Simon A, Kuijpers TW, van Montfrans JM. Immunoglobulin Replacement Therapy Versus Antibiotic Prophylaxis as Treatment for Incomplete Primary Antibody Deficiency. J Clin Immunol 2021;41:382-92. [PMID: 33206257 DOI: 10.1007/s10875-020-00841-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
155 Na IK, Buckland M, Agostini C, Edgar JDM, Friman V, Michallet M, Sánchez-Ramón S, Scheibenbogen C, Quinti I. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Eur J Haematol 2019;102:447-56. [PMID: 30801785 DOI: 10.1111/ejh.13223] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
156 Kim BH, Lee S. Sophoricoside from Sophora japonica ameliorates allergic asthma by preventing mast cell activation and CD4+ T cell differentiation in ovalbumin-induced mice. Biomed Pharmacother 2021;133:111029. [PMID: 33254020 DOI: 10.1016/j.biopha.2020.111029] [Reference Citation Analysis]
157 Melamed I, Kobayashi RH, O'Connor M, Kobayashi AL, Schechterman A, Heffron M, Canterberry S, Miranda H, Rashid N. Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome. J Child Adolesc Psychopharmacol 2021;31:118-28. [PMID: 33601937 DOI: 10.1089/cap.2020.0100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Corthésy B, Monnerat J, Lötscher M, Vonarburg C, Schaub A, Bioley G. Oral Passive Immunization With Plasma-Derived Polyreactive Secretory-Like IgA/M Partially Protects Mice Against Experimental Salmonellosis. Front Immunol 2018;9:2970. [PMID: 30619327 DOI: 10.3389/fimmu.2018.02970] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
159 Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-Manrique L, Díaz de Heredia C, Fortuny-Guasch C, García-Cadenas I, García-Vidal C, González-Vicent M, Hernani R, Kwon M, Machado M, Martínez-Gómez X, Maldonado VO, Pla CP, Piñana JL, Pomar V, Reguera-Ortega JL, Salavert M, Soler-Palacín P, Vázquez-López L, Barba P, Ruiz-Camps I. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection 2021;49:215-31. [PMID: 32979154 DOI: 10.1007/s15010-020-01521-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
160 Nordin J, Solís L, Prévot J, Mahlaoui N, Chapel H, Sánchez-Ramón S, Ali A, Seymour JW, Pergent M. The PID Principles of Care: Where Are We Now? A Global Status Report Based on the PID Life Index. Front Immunol 2021;12:780140. [PMID: 34868053 DOI: 10.3389/fimmu.2021.780140] [Reference Citation Analysis]
161 Wang S, Tang Z, Zheng X, Deng J, Wang Z. Efficacy of human immunoglobulin injection and effects on serum inflammatory cytokines in neonates with acute lung injury. Exp Ther Med 2021;22:931. [PMID: 34306200 DOI: 10.3892/etm.2021.10363] [Reference Citation Analysis]
162 Ho HE, Cunningham-Rundles C. Non-infectious Complications of Common Variable Immunodeficiency: Updated Clinical Spectrum, Sequelae, and Insights to Pathogenesis. Front Immunol. 2020;11:149. [PMID: 32117289 DOI: 10.3389/fimmu.2020.00149] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 17.0] [Reference Citation Analysis]
163 Chinn IK, Orange JS. Immunodeficiency Disorders. Pediatr Rev 2019;40:229-42. [PMID: 31043442 DOI: 10.1542/pir.2017-0308] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
164 Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, Maude SL, McCarthy PL, Mead E, Neelapu SS, Neilan TG, Santomasso BD, Shpall EJ, Teachey DT, Turtle CJ, Whitehead T, Grupp SA. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer 2020;8:e001511. [PMID: 33335028 DOI: 10.1136/jitc-2020-001511] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 14.5] [Reference Citation Analysis]
165 Martinez C, Wallenhorst C, van Nunen S. Intravenous immunoglobulin and the current risk of moderate and severe anaphylactic events, a cohort study. Clin Exp Immunol 2021;206:384-94. [PMID: 34562316 DOI: 10.1111/cei.13665] [Reference Citation Analysis]
166 Wijetilleka S, Jayne D, Mukhtyar C, Karim MY. Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases. Lupus Sci Med 2019;6:e000337. [PMID: 31413852 DOI: 10.1136/lupus-2019-000337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
167 Baumann U, Fasshauer M, Pausch C, Wittkowski H, Hermann C, Pittrow D, Borte M. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases. Immunotherapy 2021. [PMID: 34743590 DOI: 10.2217/imt-2021-0167] [Reference Citation Analysis]
168 Dulek DE, Fuhlbrigge RC, Tribble AC, Connelly JA, Loi MM, El Chebib H, Chandrakasan S, Otto WR, Diorio C, Keim G, Walkovich K, Jaggi P, Girotto JE, Yarbrough A, Behrens EM, Cron RQ, Bassiri H. Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients. J Pediatric Infect Dis Soc 2020;9:716-37. [PMID: 32808988 DOI: 10.1093/jpids/piaa098] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
169 Bonagura VR. Personalized IgG Replacement Therapy for Patients with B cell Inborn Errors of Immunity. J Clin Immunol 2021;41:713-7. [PMID: 33740169 DOI: 10.1007/s10875-021-00995-8] [Reference Citation Analysis]
170 Wasserman RL; HyQvia Experience Study Group. Clinical Practice Experience with HyQvia in Adults Using Alternative Dosing Regimens and Pediatric Patients: A Retrospective Study. Adv Ther 2020;37:1536-49. [PMID: 32124273 DOI: 10.1007/s12325-020-01264-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
171 Perez EE, Hébert J, Ellis AK, Alpan O, Lumry WR, Shapiro R, Suez D, Mandujano JF, Wasserman RL. Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies. Front Immunol 2021;12:707463. [PMID: 34305948 DOI: 10.3389/fimmu.2021.707463] [Reference Citation Analysis]
172 Prevot J, Jolles S. Global immunoglobulin supply: steaming towards the iceberg? Curr Opin Allergy Clin Immunol 2020;20:557-64. [PMID: 33044340 DOI: 10.1097/ACI.0000000000000696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
173 LaFon DC, Nahm MH. Measuring quantity and function of pneumococcal antibodies in immunoglobulin products. Transfusion 2018;58 Suppl 3:3114-20. [PMID: 30536435 DOI: 10.1111/trf.15015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
174 Das M, Karnam A, Stephen-Victor E, Gilardin L, Bhatt B, Kumar Sharma V, Rambabu N, Patil V, Lecerf M, Käsermann F, Bruneval P, Narayanaswamy Balaji K, Benveniste O, Kaveri SV, Bayry J. Intravenous immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear cells by inducing autophagy. Cell Death Dis 2020;11:50. [PMID: 31974400 DOI: 10.1038/s41419-020-2249-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
175 Burnouf T. What can be learned in the snake antivenom field from the developments in human plasma derived products? Toxicon 2018;146:77-86. [PMID: 29621528 DOI: 10.1016/j.toxicon.2018.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
176 Karakulska-Prystupiuk E, Dwilewicz-Trojaczek J, Drozd-Sokołowska J, Kmin E, Chlebus M, Szczypińska K, Boguradzki P, Tomaszewska A, Mądry K, Biliński J, Basak GW, Jędrzejczak WW. Prevalence of hypogammaglobulinemia and its management with subcutaneous immunoglobulin supplementation in patients after allogeneic hematopoietic stem cell transplantation-a single-center analysis. Ann Hematol 2021;100:3007-16. [PMID: 34477951 DOI: 10.1007/s00277-021-04649-y] [Reference Citation Analysis]
177 De Angelis V, Breda A. Trends in Plasma Toll Fractionation for Self Sufficiency of Plasma-Derived Medicinal Products in Italy. Transfus Med Hemother 2019;46:232-8. [PMID: 31700505 DOI: 10.1159/000496750] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
178 Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother 2020;131:110698. [PMID: 32920514 DOI: 10.1016/j.biopha.2020.110698] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 14.0] [Reference Citation Analysis]
179 Du X, Wang Z, Lv Z, Ma L, Ye S, Liu F, Zhang R, Cao H, Li C. Content of anti-β-amyloid42 oligomers antibodies in multiple batches from different immunoglobulin preparations. Biologicals 2020;65:25-32. [PMID: 32165080 DOI: 10.1016/j.biologicals.2020.02.004] [Reference Citation Analysis]
180 Bruijstens AL, Wendel EM, Lechner C, Bartels F, Finke C, Breu M, Flet-Berliac L, de Chalus A, Adamsbaum C, Capobianco M, Laetitia G, Hacohen Y, Hemingway C, Wassmer E, Lim M, Baumann M, Wickström R, Armangue T, Rostasy K, Deiva K, Neuteboom RF. E.U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 2020;29:41-53. [PMID: 33176999 DOI: 10.1016/j.ejpn.2020.10.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
181 Ballow M. Practical aspects of immunoglobulin replacement. Ann Allergy Asthma Immunol 2017;119:299-303. [PMID: 28958372 DOI: 10.1016/j.anai.2017.07.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
182 Balch A, Wilkes J, Thorell E, Pavia A, Sherwin CMT, Enioutina EY. Changing trends in IVIG use in pediatric patients: A retrospective review of practices in a network of major USA pediatric hospitals. Int Immunopharmacol 2019;76:105868. [PMID: 31487613 DOI: 10.1016/j.intimp.2019.105868] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
183 Garraud O, Aubron C, Ozier Y, Coppo P, Tissot JD. Plasma for direct therapeutic use, for today and tomorrow: A short critical overview. Transfus Clin Biol 2018;25:281-6. [PMID: 30131289 DOI: 10.1016/j.tracli.2018.07.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
184 Sánchez-Ramón S, Bermúdez A, González-Granado LI, Rodríguez-Gallego C, Sastre A, Soler-Palacín P; ID-Signal Onco-Haematology Group. Primary and Secondary Immunodeficiency Diseases in Oncohaematology: Warning Signs, Diagnosis, and Management. Front Immunol 2019;10:586. [PMID: 30984175 DOI: 10.3389/fimmu.2019.00586] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
185 Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Ann Allergy Asthma Immunol 2019;123:454-60. [PMID: 31349011 DOI: 10.1016/j.anai.2019.07.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
186 Vitiello G, Emmi G, Silvestri E, Di Scala G, Palterer B, Parronchi P. Intravenous immunoglobulin therapy: a snapshot for the internist. Intern Emerg Med 2019;14:1041-9. [PMID: 31309519 DOI: 10.1007/s11739-019-02150-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
187 Maddur MS, Stephen-Victor E, Das M, Prakhar P, Sharma VK, Singh V, Rabin M, Trinath J, Balaji KN, Bolgert F, Vallat JM, Magy L, Kaveri SV, Bayry J. Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy. J Neuroinflammation 2017;14:58. [PMID: 28320438 DOI: 10.1186/s12974-017-0818-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
188 Derman BA, Schlei Z, Parsad S, Mullane K, Knoebel RW. Changes in Intravenous Immunoglobulin Usage for Hypogammaglobulinemia After Implementation of a Stewardship Program. JCO Oncol Pract 2021;17:e445-53. [PMID: 32822257 DOI: 10.1200/OP.20.00312] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
189 Ji YL, Wu Y, Qiu Z, Ming H, Zhang Y, Zhang AN, Leng Y, Xia ZY. The Pathogenesis and Treatment of COVID-19: A System Review. Biomed Environ Sci 2021;34:50-60. [PMID: 33531107 DOI: 10.3967/bes2021.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
190 Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Hernandez Tejada FN, Martin PL, Auletta J, Choi SW, Bajwa R, Dailey Garnes N, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 2021;18:435-53. [PMID: 33608690 DOI: 10.1038/s41571-021-00474-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
191 Lei WT, Lin CY, Kao YH, Lee CH, Lin CH, Shyur SD, Yang KD, Chen JH. The risk of hospitalization for respiratory tract infection (RTI) in children who are treated with high-dose IVIG in Kawasaki Disease: a nationwide population-based matched cohort study. PeerJ 2018;6:e4539. [PMID: 29593942 DOI: 10.7717/peerj.4539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
192 Odnoletkova I, Kindle G, Quinti I, Grimbacher B, Knerr V, Gathmann B, Ehl S, Mahlaoui N, Van Wilder P, Bogaerts K, de Vries E; Plasma Protein Therapeutics Association (PPTA) Taskforce. The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data. Orphanet J Rare Dis. 2018;13:201. [PMID: 30419968 DOI: 10.1186/s13023-018-0941-0] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 14.5] [Reference Citation Analysis]
193 Pavlakou P, Papasotiriou M, Ntrinias T, Kourakli A, Bratsiakou A, Goumenos DS, Papachristou E. Case Report: Kidney Transplantation in a Patient With Acquired Agammaglobulinemia and SLE. Issues and Challenges. Front Med (Lausanne) 2021;8:665475. [PMID: 33777986 DOI: 10.3389/fmed.2021.665475] [Reference Citation Analysis]
194 Chen KZ, Kazi R, Porter CC, Qu CK. Germline mutations: many roles in leukemogenesis. Curr Opin Hematol 2020;27:288-93. [PMID: 32487806 DOI: 10.1097/MOH.0000000000000596] [Reference Citation Analysis]
195 Peter HH, Ochs HD, Cunningham-Rundles C, Vinh DC, Kiessling P, Greve B, Jolles S. Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations. J Allergy Clin Immunol 2020;146:479-491.e5. [PMID: 32896308 DOI: 10.1016/j.jaci.2020.07.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
196 Meckley LM, Wu Y, Tzivelekis S, Gandhi V, Gladiator A. Infusion parameters of 20% subcutaneous immunoglobulin for primary immunodeficiency diseases among patient support program participants. Ann Allergy Asthma Immunol 2021:S1081-1206(21)00488-9. [PMID: 34224864 DOI: 10.1016/j.anai.2021.06.023] [Reference Citation Analysis]
197 Karnam A, Stephen-Victor E, Das M, Magy L, Vallat JM, Bolgert F, Simon-Loriere E, Kaveri SV, Sakuntabhai A, Bayry J. Does intravenous immunoglobulin therapy in Guillain-Barré syndrome patients interfere with serological Zika detection? Autoimmun Rev 2019;18:632-3. [PMID: 30959213 DOI: 10.1016/j.autrev.2019.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
198 Navarro-Triviño FJ, Pérez-López I, Ruíz-Villaverde R. Dermatology and Immunoglobulin Therapy: Who to Treat and How to Administer Immunoglobulins. Actas Dermosifiliogr (Engl Ed) 2018;109:323-30. [PMID: 29429551 DOI: 10.1016/j.ad.2017.11.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
199 Wijetilleka S, Mukhtyar C, Jayne D, Ala A, Bright P, Chinoy H, Harper L, Kazmi M, Kiani-Alikhan S, Li C, Misbah S, Oni L, Price-Kuehne F, Salama A, Workman S, Wrench D, Karim MY. Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review. Autoimmun Rev 2019;18:535-41. [PMID: 30844552 DOI: 10.1016/j.autrev.2019.03.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
200 Tharmalingam T, Han X, Wozniak A, Saward L. Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases. Hum Vaccin Immunother 2021;:1-20. [PMID: 34010089 DOI: 10.1080/21645515.2021.1886560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Tong TN, Blacquiere M, Sakac D, Burke-Murphy E, Yi Q, Callum J, Cserti-Gazdewich C, Parmar N, Shehata N, Pavenski K, Lau W, Lin Y, Lieberman L, Branch DR, Pendergrast J. The utility of a monocyte monolayer assay in the assessment of intravenous immunoglobulin-associated hemolysis. Transfusion 2020;60:3010-8. [PMID: 33091964 DOI: 10.1111/trf.16131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Cordero E, Goycochea-Valdivia W, Mendez-Echevarria A, Allende LM, Alsina L, Bravo García-Morato M, Gil-Herrera J, Gudiol C, Len-Abad O, López-Medrano F, Moreno-Pérez D, Muñoz P, Olbrich P, Sánchez-Ramón S, Soler-Palacín P, Aguilera Cros C, Arostegui JI, Badell Serra I, Carbone J, Fortún J, Gonzalez-Granado LI, López-Granados E, Lucena JM, Parody R, Ramakers J, Regueiro JR, Rivière JG, Roca-Oporto C, Rodríguez Pena R, Santos-Pérez JL, Rodríguez-Gallego C, Neth O. Executive Summary of the Consensus Document on the Diagnosis and Management of Patients with Primary Immunodeficiencies. J Allergy Clin Immunol Pract 2020;8:3342-7. [PMID: 33161963 DOI: 10.1016/j.jaip.2020.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
203 Cui Y, Qu Y, Yin K, Zhang X, Lin H. Selenomethionine ameliorates LPS-induced intestinal immune dysfunction in chicken jejunum. Metallomics 2021;13:mfab003. [PMID: 33693770 DOI: 10.1093/mtomcs/mfab003] [Reference Citation Analysis]
204 Abbas A, Rajabally YA. Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review. Curr Drug Saf 2019;14:3-13. [PMID: 30332974 DOI: 10.2174/1574886313666181017121139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
205 Paris K, Haddad E, Borte M, Brodszki N, Dérfalvi B, Maródi L, Hussain I, Darter A, Engl W, Leibl H, McCoy B, Yel L. Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies. Immunotherapy 2019;11:397-406. [PMID: 30626238 DOI: 10.2217/imt-2018-0088] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
206 Sheianov MV, Udalov YD, Ochkin SS, Bashkov AN, Samoilov AS. Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases. Cureus 2020;12:e9038. [PMID: 32656044 DOI: 10.7759/cureus.9038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
207 Wu HY, Pan CT, Cheng CF, Lin CY, Chang SN, Chen YC, Wang CY, Chen YF, Chen CY, Ma MH, Hwang JJ. Combined intravenous immunoglobulin and baricitinib treatment for severe COVID-19 with rhabdomyolysis: A case report. J Formos Med Assoc 2021;120:1777-81. [PMID: 33838985 DOI: 10.1016/j.jfma.2021.03.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
208 Napoli C, Benincasa G, Criscuolo C, Faenza M, Liberato C, Rusciano M. Immune reactivity during COVID-19: Implications for treatment. Immunol Lett 2021;231:28-34. [PMID: 33421440 DOI: 10.1016/j.imlet.2021.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
209 Ueda M, Berger M, Gale RP, Lazarus HM. Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. Blood Reviews 2018;32:106-15. [DOI: 10.1016/j.blre.2017.09.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
210 Tenembaum S, Yeh EA; Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC). Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis. Front Pediatr 2020;8:339. [PMID: 32671002 DOI: 10.3389/fped.2020.00339] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
211 Wasserman RL. Gammaplex® 5 and 10% in the treatment of primary immunodeficiency and chronic immune thrombocytopenic purpura. Immunotherapy 2017;9:1071-88. [PMID: 29032734 DOI: 10.2217/imt-2017-0071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
212 Soler-Palacín P, de Gracia J, González-Granado LI, Martín C, Rodríguez-Gallego C, Sánchez-Ramón S; Lung ID-Signal Group. Primary immunodeficiency diseases in lung disease: warning signs, diagnosis and management. Respir Res 2018;19:219. [PMID: 30419907 DOI: 10.1186/s12931-018-0923-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
213 El-Sayed ZA, Abramova I, Aldave JC, Al-Herz W, Bezrodnik L, Boukari R, Bousfiha AA, Cancrini C, Condino-Neto A, Dbaibo G, Derfalvi B, Dogu F, Edgar JDM, Eley B, El-Owaidy RH, Espinosa-Padilla SE, Galal N, Haerynck F, Hanna-Wakim R, Hossny E, Ikinciogullari A, Kamal E, Kanegane H, Kechout N, Lau YL, Morio T, Moschese V, Neves JF, Ouederni M, Paganelli R, Paris K, Pignata C, Plebani A, Qamar FN, Qureshi S, Radhakrishnan N, Rezaei N, Rosario N, Routes J, Sanchez B, Sediva A, Seppanen MR, Serrano EG, Shcherbina A, Singh S, Siniah S, Spadaro G, Tang M, Vinet AM, Volokha A, Sullivan KE. X-linked agammaglobulinemia (XLA):Phenotype, diagnosis, and therapeutic challenges around the world. World Allergy Organ J 2019;12:100018. [PMID: 30937141 DOI: 10.1016/j.waojou.2019.100018] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
214 Tichy EM, Prosser B, Doyle D. Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease Management in Neuromuscular Disorders. J Pharm Pract 2020;:897190020938212. [PMID: 32677504 DOI: 10.1177/0897190020938212] [Reference Citation Analysis]
215 Bozza S, Käsermann F, Kaveri SV, Romani L, Bayry J. Intravenous immunoglobulin protects from experimental allergic bronchopulmonary aspergillosis via a sialylation-dependent mechanism. Eur J Immunol 2019;49:195-8. [PMID: 30267564 DOI: 10.1002/eji.201847774] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
216 Shemer A, Kivity S, Shoenfeld Y. Clinical indications for intravenous immunoglobulin utilization in a tertiary medical center: a 9-year retrospective study. Transfusion 2018;58:430-8. [PMID: 29193136 DOI: 10.1111/trf.14427] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]